SCHEMBL14819122

SCHEMBL14819122

COCC(COP(=O)(O)OCC[N+](C)(C)C)OCCCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP3 P05413 1/20 0.50
▸ RECQL P46063 1/20 0.43
▸ LPAR1 Q92633 4/20 0.40
▸ LPAR3 Q9UBY5 4/20 0.40
▸ LPAR6 P43657 2/20 0.40
▸ LPAR4 Q99677 2/20 0.40
▸ LPAR5 Q9H1C0 2/20 0.40
▸ LPAR2 Q9HBW0 2/20 0.40
▸ MAPK1 P28482 5/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ GMNN O75496 3/20 0.38
▸ LMNA P02545 3/20 0.38
▸ BLM P54132 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ NPSR1 Q6W5P4 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ TP53 P04637 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2605938 0.96 FABP3 (0.52) FABP3RECQLLPAR1LPAR3LPAR6
SCHEMBL16982402 0.93 FABP3 (0.50) FABP3RECQLMAPK1MEN1GMNN
SCHEMBL15336411 0.89 FABP3 (0.52) FABP3RECQLMAPK1MEN1GMNN
SCHEMBL27966574 0.87 RECQL (0.59) FABP3RECQLLPAR1LPAR3LPAR2
Vb-201 SCHEMBL19327154 0.84 RECQL (0.64) FABP3RECQLLPAR1LPAR3LPAR2
Vb-201 SCHEMBL15942776 0.84 RECQL (0.64) FABP3RECQLLPAR1LPAR3LPAR2
SCHEMBL8746968 0.84 RECQL (0.64) FABP3RECQLLPAR1LPAR3LPAR2
SCHEMBL12345691 0.84 RECQL (0.64) FABP3RECQLLPAR1LPAR3LPAR2
SCHEMBL15164286 0.84 RECQL (0.64) FABP3RECQLLPAR1LPAR3LPAR2
SCHEMBL27966578 0.84 RECQL (0.64) FABP3RECQLLPAR1LPAR3LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170246197-A1 High-Purity Phospholipids VASCULAR BIOGENICS LTD. (IL) 2017-08-31 — — US disclosed
US-9006217-B2 High-purity phospholipids VASCULAR BIOGENICS LTD. (IL) 2015-04-14 — — US disclosed
US-8569529-B2 High-purity phospholipids VASCULAR BIOGENICS LTD. (IL) 2013-10-29 — — US disclosed
US-20130237720-A1 High-Purity Phospholipids VASCULAR BIOGENICS LTD. (IL) 2013-09-12 — — US disclosed
US-20130079540-A1 High-Purity Phospholipids VASCULAR BIOGENICS LTD. (IL) 2013-03-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079540-A1 High-Purity Phospholipids PHOSPHO1, SGMS1, SGMS2 FABP3 423/4885RECQL 3038/4885LPAR1 77/4885
US-20170246197-A1 High-Purity Phospholipids PHOSPHO1, SGMS1, SGMS2 FABP3 478/4885RECQL 2816/4885LPAR1 71/4885
US-20130237720-A1 High-Purity Phospholipids PHOSPHO1, SGMS1, SGMS2 FABP3 478/4885RECQL 2816/4885LPAR1 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback